Treated Dentine Matrix and Platelet Rich Fibrin in Induction of Root Formation of Non-Vital Immature Permanent Teeth
NCT ID: NCT05775081
Last Updated: 2024-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2021-07-15
2023-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Combined Blood Clot and Platelet Rich Fibrin Scaffolds in Regeneration of Necrotic Immature Permanent Teeth
NCT04390854
Evaluation of Platelet-rich Fibrin for Revascularization of Immature Permanent Teeth Versus Standard Apexification
NCT06693349
Clinical and Radiographic Outcome of Regeneration in Immature Permanent Human Teeth Using a New Scaffold
NCT06812351
Injectable Platelet Rich Fibrin With Collagen Matrix in Treatment of Multiple Gingival Recession.
NCT05389059
Regenerative Ability of Immature Necrotic Permanent Teeth Using Different Scaffolds
NCT06693739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be randomly allocated into 2 groups using sealed envelope method of randomization
Group (A):
Teeth to be treated by h-TDM paste (n=10).
Group (B):
Teeth to be treated by platelet rich fibrin (PRF) regeneration (n=10).
B) Procedures:
Diagnosis of pulp necrosis, clinical and radiographic examination. 11 For each patient, the protocol of treatment is composed of 7 sessions. The follow-up takes place over a 15 months' period. Day 0 is considered as the day of the first treatment session.
I- Day 0:
* Pre-operative Cone Beam Computed Tomography (CBCT) is taken at this visit.
* Calcium hydroxide canal conditioning for 2 weeks regardless of the treatment group. This is done in the following sequence:
* Administration of local anesthesia, then rubber dam isolation.
* Preparing an access cavity and establishing the working length by taking a radiograph with a file inserted into the root canal within 2 mm of the radiographic apex.
* The canal is cleaned by irrigation with 1.25% sodium hypochlorite and the use of manual files. The cleaning and shaping are realized with files with a very light parietal action to avoid the canal widening and the weakening of the root walls. Above all, it consists in removing the pulp remnants.
* Then, the canal is dried with paper point and can be filled with calcium hydroxide. Calcium hydroxide paste is prepared by mixing the calcium hydroxide powder and Barium Sulfate as a radio-opacifier mixed with sterile distilled water. A plug of calcium hydroxide is placed in the canal and condensed to the apical end of the root with a plugger. Other layers of calcium hydroxide are placed till complete canal filling.
* The intracanal dressing quality is checked with a radiograph. The access cavity is temporarily sealed with a resin modified glass ionomer cement. This calcium hydroxide canal conditioning is performed for all patients to allow the complete disinfection.
II- Day 0+15:
This session starts with administration of local anesthesia, placement of a rubber dam and the removal of all the calcium hydroxide by copious saline irrigation. Then, treatment according to the assigned group:
Group A (h-TDM paste):
1. Preparation of h-TDM:
Mentioned before.
2. Preparation of h-TDM paste:
Mentioned before. 3- Operative procedures:
* The h-TDM paste will be placed into the canal by sterile amalgam carrier and condensed to the apical end of the root with a plugger to create a 4 mm apical plug. Radiograph will be taken to verify proper placement of the mixture. Then, 1mm of MTA will be placed over this paste.
* Then, the access cavity will be filled with resin modified glass ionomer.
Group B (PRF regeneration):
13
* Ten ml of venous blood will be withdrawn from the child's forearm to a sterile test tube without anticoagulant and will be centrifuged in 3000 rpm for 10 minutes to prepare PRF, which appears as a membrane between the free plasma in the top and RBCs in the bottom of the tube.
* Platelet rich fibrin will be withdrawn from the test tube using sterile tweezer and put into sterile gauze and cut into small pieces using sterile scissor.
* Root canal will be copiously irrigated by sterile saline and dried with sterile paper points. Platelet rich fibrin small pieces will be condensed into the root canal till the apex using sterile plugger. Then, 2mm of MTA will be placed over the PRF till CEJ. Then, access cavity will be sealed by glass ionomer.
III- 3 months:
Clinical and radiographic control for all patients.
IV- 6 months:
Clinical and radiographic control for all patients.
V- 9 months:
Clinical and radiographic control for all patients.
VI- 12 months:
• Clinical and radiographic control for all patients.
VII- 15 months:
* Clinical and radiographic control for all patients.
* CBCT is taken at this visit. The x-rays of each patient are taken with the aid of film holder to be standardized and reproducible, so that they can be compared.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated Dentine Matrix (TDM)
Participants treated with TDM paste
Regenerative endodontic procedues
Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
Platelet Rich Fibrin (PRF)
Participants treated with PRF
Regenerative endodontic procedues
Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regenerative endodontic procedues
Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Immunosuppression
* Chronic systemic disease if a treatment is required
* Periodontal disease
6 Years
11 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed A Asal, MDS
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Ibrahim H Elkalla, PhD
Role: STUDY_CHAIR
Mansoura University
Yousry M Elhawary, PhD
Role: STUDY_DIRECTOR
Mansoura University
Ashraf Y Alhsoainy, PhD
Role: STUDY_DIRECTOR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Dentistry, Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A07060721
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.